Literature DB >> 11738536

Neuropsychological impairments in neuroleptic-responder vs. -nonresponder schizophrenic patients and healthy volunteers.

Ridha Joober1, Guy A Rouleau, Samarthji Lal, Michael Dixon, Gillian O'Driscoll, Roberta Palmour, Lawrence Annable, David Bloom, Pierre Lalonde, Alain Labelle, Chawki Benkelfat.   

Abstract

To determine whether two groups of schizophrenic patients representing the two extremes of the neuroleptic response-spectrum (consistent responders vs. consistent nonresponders) differ with respect to their neuropsychological profile. Neuroleptic-responder (R; n=36) and -nonresponder (NR; n=39) schizophrenic patients were recruited according to a priori defined criteria of responsiveness to typical neuroleptics. Seven neuropsychological domains were assessed and compared between groups: attention-vigilance, abstraction-flexibility, spatial organization, visual-motor processing, visual memory, verbal abilities, and verbal memory and learning. All measures were standardized using the scores of 36 healthy volunteers. NR schizophrenic patients performed worse in all neuropsychological domains compared to normal controls and R schizophrenic patients. However, only performances on visual memory, verbal abilities, and verbal memory and learning were significantly poorer in NR compared to R patients. Only the latter domain significantly differentiated NR patients from the other two groups. R patients performed at an intermediate level in all domains. This report of differences in neuropsychological profile between neuroleptic-responder and -nonresponder schizophrenic patients adds to the growing evidence supporting the value of distinguishing schizophrenic patients on the basis of their therapeutic response to neuroleptics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11738536     DOI: 10.1016/s0920-9964(01)00279-1

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  16 in total

Review 1.  Neurocognition: clinical and functional outcomes in schizophrenia.

Authors:  Martin Lepage; Michael Bodnar; Christopher R Bowie
Journal:  Can J Psychiatry       Date:  2014-01       Impact factor: 4.356

Review 2.  Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives.

Authors:  Frederick C Nucifora; Edgar Woznica; Brian J Lee; Nicola Cascella; Akira Sawa
Journal:  Neurobiol Dis       Date:  2018-08-29       Impact factor: 5.996

3.  Direct measure of the de novo mutation rate in autism and schizophrenia cohorts.

Authors:  Philip Awadalla; Julie Gauthier; Rachel A Myers; Ferran Casals; Fadi F Hamdan; Alexander R Griffing; Mélanie Côté; Edouard Henrion; Dan Spiegelman; Julien Tarabeux; Amélie Piton; Yan Yang; Adam Boyko; Carlos Bustamante; Lan Xiong; Judith L Rapoport; Anjené M Addington; J Lynn E DeLisi; Marie-Odile Krebs; Ridha Joober; Bruno Millet; Eric Fombonne; Laurent Mottron; Martine Zilversmit; Jon Keebler; Hussein Daoud; Claude Marineau; Marie-Hélène Roy-Gagnon; Marie-Pierre Dubé; Adam Eyre-Walker; Pierre Drapeau; Eric A Stone; Ronald G Lafrenière; Guy A Rouleau
Journal:  Am J Hum Genet       Date:  2010-09-10       Impact factor: 11.025

4.  Hippocampus and cognitive domain deficits in treatment-resistant schizophrenia: A comparison with matched treatment-responsive patients and healthy controls✰,✰✰,★,★★.

Authors:  Junchao Huang; Yu Zhu; Fengmei Fan; Song Chen; Yuan Hong; Yimin Cui; Xingguang Luo; Shuping Tan; Zhiren Wang; Lan Shang; Ying Yuan; Jianxin Zhang; Fude Yang; Chiang-Shan R Li; Laura M Rowland; Peter Kochunov; Fengyu Zhang; L Elliot Hong; Yunlong Tan
Journal:  Psychiatry Res Neuroimaging       Date:  2020-02-04       Impact factor: 2.376

Review 5.  Genetics of schizophrenia: from animal models to clinical studies.

Authors:  Ridha Joober; Patricia Boksa; Chawki Benkelfat; Guy Rouleau
Journal:  J Psychiatry Neurosci       Date:  2002-09       Impact factor: 6.186

6.  A population genetic approach to mapping neurological disorder genes using deep resequencing.

Authors:  Rachel A Myers; Ferran Casals; Julie Gauthier; Fadi F Hamdan; Jon Keebler; Adam R Boyko; Carlos D Bustamante; Amelie M Piton; Dan Spiegelman; Edouard Henrion; Martine Zilversmit; Julie Hussin; Jacklyn Quinlan; Yan Yang; Ronald G Lafrenière; Alexander R Griffing; Eric A Stone; Guy A Rouleau; Philip Awadalla
Journal:  PLoS Genet       Date:  2011-02-24       Impact factor: 5.917

7.  Association study of the trinucleotide repeat polymorphism within SMARCA2 and schizophrenia.

Authors:  Sarojini Sengupta; Lan Xiong; Ferid Fathalli; Chawki Benkelfat; Karim Tabbane; Zoltan Danics; Alain Labelle; Samarthji Lal; Marie-Odile Krebs; Guy Rouleau; Ridha Joober
Journal:  BMC Genet       Date:  2006-06-03       Impact factor: 2.797

Review 8.  Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review.

Authors:  Amy L Gillespie; Ruta Samanaite; Jonathan Mill; Alice Egerton; James H MacCabe
Journal:  BMC Psychiatry       Date:  2017-01-13       Impact factor: 3.630

9.  Interacting Roles of COMT and GAD1 Genes in Patients with Treatment-Resistant Schizophrenia: a Genetic Association Study of Schizophrenia Patients and Healthy Controls.

Authors:  Masanobu Kogure; Nobuhisa Kanahara; Atsuhiro Miyazawa; Kengo Oishi; Yusuke Nakata; Yasunori Oda; Masaomi Iyo
Journal:  J Mol Neurosci       Date:  2021-06-14       Impact factor: 3.444

10.  Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia.

Authors:  J Tarabeux; O Kebir; J Gauthier; F F Hamdan; L Xiong; A Piton; D Spiegelman; É Henrion; B Millet; F Fathalli; R Joober; J L Rapoport; L E DeLisi; É Fombonne; L Mottron; N Forget-Dubois; M Boivin; J L Michaud; P Drapeau; R G Lafrenière; G A Rouleau; M-O Krebs
Journal:  Transl Psychiatry       Date:  2011-11-15       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.